Paul Hideo Opgenorth

CIK: 0002033517

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)1 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

EXOZ

EXOZYMES INC.

Officer

Discretionary Trading P&L

Holdings

Transaction History (3 total)

EXOZ
EXOZYMES INC.
Apr 1, 2026
Award(A)
Direct
4K shares at avg. $8.44$34K
EXOZ
EXOZYMES INC.
Jun 13, 2025
Award(A)
Direct
3K shares at avg. $12.54$37K
IZTC
Invizyne Technologies Inc
Nov 8, 2024
Conversion(C)
Direct
2.3K shares at avg. $6.40$15K

		Type	Shares	Price		Ownership
Apr 1, 2026	EXOZ EXOZYMES INC.	Award(A)	3,999	$8.44	$33,752	Direct
Jun 13, 2025	EXOZ EXOZYMES INC.	Award(A)	2,990	$12.54	$37,495	Direct
Nov 8, 2024	IZTC Invizyne Technologies Inc	Conversion(C)	2,344	$6.40	$15,002	Direct

1-3 of 3 transactions

About Opgenorth Paul Hideo

Opgenorth Paul Hideo (SEC CIK 0002033517) files insider reports with the SEC as Vice President, Development of EXOZYMES INC. (EXOZ).

Signal8 holds 4 ownership filings by Opgenorth Paul Hideo (1 Form 3, 3 Form 4), filed between Nov 18, 2024 and Apr 8, 2026. Those filings report 3 transactions, from Nov 8, 2024 to Apr 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Opgenorth Paul Hideo's filings is in MONROVIA, CA.

Recent filings by Opgenorth Paul Hideo

Apr 1, 2026: Grant or award of EXOZ shares (Form 4, code A).
Jun 13, 2025: Grant or award of EXOZ shares (Form 4, code A).
Nov 8, 2024: Conversion of IZTC shares (Form 4, code C).

Other insiders filing for EXOZYMES INC. (EXOZ)

Perriman Damien Alan, Chief Commercial Officer
Korman Tyler Paz, Chief Scientific Officer
Rayo Edgardo Javier, Director
MARLETT CHRISTOPHER A, Director
Lalonde James Joseph, Director
DIGIANDOMENICO ANTHONY, Director

How to read Form 4 transaction codes